How To Write A Death Anniversary Invitation

CANCER: RISKS ASSOCIATED WITH DRUGS TO FIGHT ANAEMIA chemotherapy

Among the side effects of chemotherapy are those represented from anemia, a situation which leads the patient to a variety of ailments in addition to the effects of care and disease that they try to defeat. That anemia can be considered a consequence of chemotherapy is also shown the need for transfusion even di sangue quando l’emoglobina scende al di sotto di 8 g/dL.


La tossicità dei farmaci chemioterapici è data dal fatto che tali molecole farmacologiche non riescono a discernere le cellule sane da quelle maligne col risultato che il successo terapeutico non è del tutto disgiunto da quello tossico e potenzialmente letale della stessa terapia.


Se oggi parliamo di anemia associata alla chemioterapia è per segnalare un’altra evidenza che occorre ricordare e che riguarda il nuovo piano messo in atto dalla Food and Drug Administration che si rivolge ai medici che curano pazienti affetti da cancro trattati con la chemioterapia e che al contempo assumono farmaci in grado di stimolare l’eritropoietina (ESA). Recall that the eritropietina is a glycoprotein hormone produced by the kidneys in humans and to a lesser extent by the liver and brain, which has as its primary function the regulation of the formation of red blood cells.

According to the FDA should apply the provisions of the Risk Evaluation and Mitigation Strategy and that concerns the summary that doctors must refer in order to inform their patients about the risk represented by the eritropietina stimulant drugs to the body which employs them. The drugs are included among those risky Aranesp (darbepoetin alfa) and Epogen (epoetin alfa) from Amgen, and Procrit (epoetin alfa) Johnson & Johnson. Epoetins for trial researchers can not only increase the risk of death from cancer patients treated with these drug molecules, but also because of other tumors themselves, added to arrive at a higher risk of heart failure, stroke and heart attack.

Studies have shown that epoetins can cause cancer and increase mortality in patients with cancer. In addition, ESAs may increase the risk of heart failure, myocardial infarction and stroke.
Source: FDA, 2010 XagenaHeadlines2010


SOURCE: tantasalute.it